Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
December 13 2017 - 7:00AM
Business Wire
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced
that it has been selected for addition to the NASDAQ Biotechnology
Index (NASDAQ: NBI) effective prior to the market open on Monday,
December 18, 2017.
The NASDAQ Biotechnology Index is designed to track the
performance of a set of NASDAQ-listed securities that are
classified as either biotechnology or pharmaceutical according to
the Industry Classification Benchmark. The NASDAQ Biotechnology
Index is re-ranked annually. For more information about the NASDAQ
Biotechnology Index visit indexes.nasdaqomx.com.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical
company focused on applying its DCE Platform® (deuterated chemical
entity platform) to create novel medicines designed to address
unmet patient needs. The Company’s approach starts with approved
drugs in which deuterium substitution has the potential to enhance
clinical safety, tolerability or efficacy. Concert has a broad
pipeline of innovative medicines targeting autoimmune and
inflammatory diseases and central nervous systems (CNS) disorders.
For more information please visit www.concertpharma.com.
Concert Pharmaceuticals Inc., the CoNCERT
Pharmaceuticals Inc. logo and DCE Platform are registered
trademarks of Concert Pharmaceuticals, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171213005089/en/
For Investors:Concert Pharmaceuticals, Inc.Justine Koenigsberg,
781-674-5284ir@concertpharma.comorFor Media:The Yates
NetworkKathryn Morris, 914-204-6412kathryn@theyatesnetwork.com
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024